C8 Ceramide (d18:1.8:0)
(Synonyms: N-辛酰基-D-神经鞘氨醇; N-Octanoyl-D-erythro-sphingosine) 目录号 : GC43105A cell-permeable ceramide analog
Cas No.:74713-59-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C8 Ceramide (d18:1.8:0) is a cell-permeable analog of naturally occurring ceramides. Unlike C2 ceramide, it is metabolized within cells to generate natural ceramides, often causing a dramatic increase in cellular ceramide levels. [1] For this reason, treatment of cells with C8 ceramide (d18:1.8:0) may more closely mimic the effects of ceramide elevation than does treatment with shorter chain ceramide analogs. C8 Ceramide (d18:1.8:0) likely mediates many diverse biological activities, as do natural ceramides. It promotes the differentiation of human keratinocytes [2] and induces apoptosis of both human leukemia cells and the U937 cell line.[1] [3]
Reference:
[1]. Karasavvas, N., Erukulla, R.K., Bittman, R., et al. Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis. Eur. J. Biochem. 236(2), 729-737 (1996).
[2]. Wakita, H., Tokura, Y., Yagi, H., et al. Keratinocyte differentiation is induced by cell-permeant ceramides and its proliferation is promoted by sphingosine. Archives of Dermatological Research 286, 350-354 (1994).
[3]. Geley, S., Hartmann, B.L., and Kofler, R. Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Letters 400, 15-18 (1997).
| Cas No. | 74713-59-0 | SDF | |
| 别名 | N-辛酰基-D-神经鞘氨醇; N-Octanoyl-D-erythro-sphingosine | ||
| 化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-octanamide | ||
| Canonical SMILES | CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCCCC)=O)CO | ||
| 分子式 | C26H51NO3 | 分子量 | 425.7 |
| 溶解度 | 20mg/mL in DMSO, 22mg/mL in DMF, 33mg/mL in Ethanol | 储存条件 | Store at -20℃, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3491 mL | 11.7454 mL | 23.4907 mL |
| 5 mM | 0.4698 mL | 2.3491 mL | 4.6981 mL |
| 10 mM | 0.2349 mL | 1.1745 mL | 2.3491 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet